|
Liver carcinoma
|
0.350 |
Biomarker
|
disease |
BEFREE |
These findings demonstrated that CDCA5 plays an important role in HCC progression.
|
31205541 |
2019 |
|
Liver carcinoma
|
0.350 |
Biomarker
|
disease |
BEFREE |
Hub genes including CDC20, AURKB, BIRC5, RRM2, MCM2, PTTG1, CDKN2A, NEK2, CENPF, RACGAP1, GNA14 and especially the new gene CDCA5 may serve as biomarkers for diagnosis, treatment and prognosis of HCC.
|
30719129 |
2019 |
|
Liver carcinoma
|
0.350 |
AlteredExpression
|
disease |
BEFREE |
The xenograft growth assay revealed that CDCA5 downregulation impeded HCC growth in vivo.
|
30015982 |
2018 |
|
Liver carcinoma
|
0.350 |
AlteredExpression
|
disease |
BEFREE |
Additionally, this study confirmed that CDCA5 expression was increased in HCC tissue versus normal liver tissue, that CDCA5 expression was associated with decreased survival and that CDCA5 knockdown using shRNA led to cell cycle arrest in the G2/M phase.
|
30497429 |
2018 |
|
Liver carcinoma
|
0.350 |
Biomarker
|
disease |
BEFREE |
The present data warrant consideration of CDCA5 as a prognostic biomarker and therapeutic target for HCC.
|
29503564 |
2018 |
|
Liver carcinoma
|
0.350 |
Biomarker
|
disease |
CTD_human |
Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
|
28284560 |
2017 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, LMTK2 binds to KLC1 to direct axonal transport of p35 and its loss may contribute to Alzheimer's disease.
|
31068217 |
2019 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings demonstrate sex differences in the effects of p35 reduction on biochemical pathways relevant to the modulation of Aβ plaque deposition and confirm the importance of examining both sexes in preclinical AD research.
|
31421203 |
2019 |
|
Cardiovascular Diseases
|
0.100 |
GeneticVariation
|
group |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Red cell distribution width determination
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
RDW - Red blood cell distribution width result
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Alzheimer's Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Cyclin-dependent kinase 5 (Cdk5), which binds to and is activated by p35, phosphorylates multiple substrates and plays an essential role in the development and function of the CNS; however, proteolytic production of p25 from p35 under stress conditions leads to the inappropriate activation of Cdk5 and contributes to hyperphosphorylation of τ and other substrates that are related to the pathogenesis of Alzheimer's disease.
|
28420695 |
2017 |
|
Alzheimer's Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This review focuses on the role of carotenoids like retinoic acid (RA), all trans retinoic acid (ATRA), lycopene and β-carotene in prevention of AD symptoms primarily through inhibition of amyloid beta (Aβ) formation, deposition and fibril formation either by reducing the levels of p35 or inhibiting corresponding enzymes.
|
21672580 |
2011 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The involvement of Cdk5 activator p35 in social isolation-triggered onset of early Alzheimer's disease-related cognitive deficit in the transgenic mice.
|
21544067 |
2011 |
|
Alzheimer's Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here, we tested the early compensation hypothesis by analyzing the levels of p25 and its precursor p35 in AD postmortem samples from different brain regions at different stages of tau pathology, using quantitative Western blots.
|
21616478 |
2011 |
|
Alzheimer's Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The calpain-mediated cleavage of p35 to p25 and the resulting aberrant activity and neurotoxicity of Cdk5 have been implicated in neurological disorders, such as Alzheimer's disease.
|
21338355 |
2011 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The amount of p25, an aberrant cleavage product of p35 that activates cyclin-dependent kinase 5 (Cdk5), is elevated in AD brains.
|
20033852 |
2010 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cdk5 phosphorylates tau at AD-specific phospho-epitopes when it associates with p25. p25 is a truncated activator, which is produced from the physiological Cdk5 activator p35 upon exposure to Abeta peptides.
|
15592431 |
2005 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Malfunctioning of cyclin-dependent kinase 5 (CDK5) through aberrant proteolytic cleavage of its neuronal activators p35 and p39 is involved in neurodegeneration in Alzheimer's disease (AD) and other neurodegenerative brain diseases.
|
15917097 |
2005 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Glucose-induced expression of the cyclin-dependent protein kinase 5 activator p35 involved in Alzheimer's disease regulates insulin gene transcription in pancreatic beta-cells.
|
14976144 |
2004 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Moreover, in vivo assay showed that silenced CDCA5 could inhibit tumor growth.
|
31324603 |
2019 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
The tumor suppression effects of CDCA5 knockdown were mediated by decreased expression of cyclin-dependent kinase 1 (CDK1) and CyclinB1, which were increased in HCC tissues comparing with adjacent normal liver tissues.
|
29503564 |
2018 |
|
Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
The present study found that increased CDCA5 expression was associated with increased tumor diameter and microvascular invasion in HCC.
|
30497429 |
2018 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Remarkably, concomitant overexpression of a 3'-UTR-truncated form of p35 promoted tumor growth in vivo and cell proliferation, cell-cycle progression, and cell survival in vitro.
|
28640256 |
2017 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Data from genetic animal models suggest that in contrast to the central role of IL-12 for tumor immune-surveillance, its close relative IL-23 rather promotes tumor growth.
|
20603238 |
2010 |